Courtney Campbell, MD
Cardiovascular Disease · Saint Louis, MONPI 1295129187
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (55.1%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by Alnylam Pharmaceuticals Inc. at 42.9% of the total. Among cardiovascular disease clinicians in MO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 108 payments — averaging $277.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alnylam Pharmaceuticals Inc.$13K
- Bridgebio Pharma, Inc.$9K
- Pfizer$6K
- Boston Scientific$864
- Novartis$436
- AstraZeneca$395
- plus $701 from 14 others
Across 5 payments — averaging $4115.83 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alnylam Pharmaceuticals Inc.$15K
- Pfizer$5K
What the payments were for
- Consulting fees$16,52055%
- Speaking & faculty fees$5,16017%
- Travel & lodging$5,53718%
- Food & beverage$2,7579%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alnylam Pharmaceuticals Inc. | 21 | $12,854 |
| Bridgebio Pharma, Inc. | 4 | $8,805 |
| Pfizer | 22 | $5,919 |
| Boston Scientific | 6 | $864 |
| Novartis | 23 | $436 |
| AstraZeneca | 4 | $395 |
| Medtronic | 1 | $137 |
| E.r. Squibb & Sons, L.L.C. | 6 | $117 |
| Novo Nordisk | 5 | $83 |
| Lilly USA, LLC | 1 | $77 |
| Heartflow, Inc. | 2 | $70 |
| Merck | 2 | $43 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $36 |
| Boehringer Ingelheim | 2 | $30 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $22 |
| Inspire Medical Systems, Inc. | 1 | $21 |
| Lantheus Medical Imaging, Inc. | 1 | $18 |
| Johnson & Johnson | 1 | $17 |
| Amgen | 1 | $15 |
| AbbVie | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ONPATTRO$9,403
- Attruby$8,750
- ORGOVYX$5,615
- WATCHMAN Access System$835
- SYMPLICITY G3$137
- ENTRESTO$131
- LEQVIO$131
- FARXIGA$123
- WAINUA$110
How this compares
$29,974 in reported general payments places this provider in the 90th percentile of 391 cardiovascular disease providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 50 | $1,367,392 |
| EliquisApixaban | 119 | $133,509 |
| JardianceEmpagliflozin | 77 | $94,278 |
| EntrestoSacubitril/Valsartan | 82 | $93,267 |
| FarxigaDapagliflozin Propanediol | 93 | $77,990 |
| OzempicSemaglutide | 13 | $19,721 |
| Repatha SureclickEvolocumab | 25 | $17,960 |
| Eplerenone | 39 | $3,860 |
| Metoprolol Succinate | 253 | $3,118 |
| Ezetimibe | 101 | $2,890 |
| Rosuvastatin Calcium | 239 | $2,823 |
| Atorvastatin Calcium | 143 | $2,004 |
| Bisoprolol Fumarate | 53 | $1,202 |
| Carvedilol | 84 | $992 |
| Olmesartan Medoxomil | 69 | $913 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $5,919 | $1,500,901169 claims |
| Boehringer IngelheimJardiance | $30 | $94,27877 claims |
| NovartisEntresto | $436 | $93,26782 claims |
| AstraZenecaFarxiga | $395 | $77,99093 claims |
| Novo NordiskOzempic | $83 | $19,72113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 391 cardiovascular disease providers in Missouri.
Other cardiovascular disease in Saint Louis
- Georges ChahoudSaint Louis$937K
- William BowenSaint Louis$726K
- Daniel KellySaint Louis$582K
- Osler Jay GuzonSaint Louis$211K
- Mohammad TahirSaint Louis$173K
- Robert RifkinSaint Louis$145K
- Martin SchwarzeSaint Louis$113K
- Joshua MitchellSaint Louis$103K
- Zainab MahmoudSaint Louis$100K
- Nizar AssiSaint Louis$81K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.